Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05531071
Other study ID # HebeiGH
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 6, 2020
Est. completion date January 12, 2021

Study information

Verified date September 2022
Source Hebei General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objective: To investigate the clinical efficacy of acupuncture combined with biofeedback electrical stimulation on female stress urinary incontinence. Methods: 90 patients diagnosed in a hospital from January 2020 to January 2021 were randomly divided into three groups A, B and C, and group A was treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times. Group B used acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times. Group C was treated with acupuncture combined with biofeedback electrical stimulation. All three groups were combined with pelvic floor muscle training. After treatment, the changes in class I, II muscle fiber, ICI-Q-SF score, and urine leakage in the 1h pad test were compared.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date January 12, 2021
Est. primary completion date January 12, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - meet the diagnostic criteria of SUI - Aged over 18 years old and have a history of sexual life - No treatment related to SUI within three months - Mental illness without cognitive dysfunction, able to cooperate with examination and treatment - Voluntarily participate and sign the informed consent Exclusion Criteria: - combined with urge urinary incontinence, uterine prolapse, vaginal anterior and posterior wall prolapse - pregnancy, postpartum lochia or abnormal vaginal bleeding - Acute phase of inflammation (pelvic cavity, vagina, urinary system) - There are metal substances such as pacemakers and metal stents in the body - Denervation of pelvic floor muscles (no sensation, no contraction) - coagulation dysfunction

Study Design


Intervention

Device:
Biofeedback electrical stimulation
treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.
Procedure:
Acupuncture
acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.
Combination Product:
Acupuncture combined with biofeedback electrical stimulation
treated with acupuncture combined with biofeedback electrical stimulation.

Locations

Country Name City State
China Caiqing Ji Shijiazhuang Hebei

Sponsors (1)

Lead Sponsor Collaborator
Hebei General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pelvic floor muscle strength Use the French Sugiyama PHENIX USB2 pelvic floor rehabilitation therapy instrument to detect the muscle strength of pelvic floor type I muscle fibers and type II muscle fibers. Class I muscle strength: amplitude height = 40%, duration 0-5s corresponds to 0-5 level muscle strength; Class II muscle strength: Amplitude height = 60%, 0 to 5 times of duration corresponds to 0 to 5 levels of muscle strength. Before treatment
Primary Pelvic floor muscle strength Use the French Sugiyama PHENIX USB2 pelvic floor rehabilitation therapy instrument to detect the muscle strength of pelvic floor type I muscle fibers and type II muscle fibers. Class I muscle strength: amplitude height = 40%, duration 0-5s corresponds to 0-5 level muscle strength; Class II muscle strength: Amplitude height = 60%, 0 to 5 times of duration corresponds to 0 to 5 levels of muscle strength. 4 weeks
Primary 1 hours urine pad test the patient empties the bladder before the test, and the urine pad is weighed and placed in the perineum. 0-15minutes, the patient drinks the mineral water prepared in advance; 16-45minutes, the patient walks as usual, going up and down the stairs; 46-60minutes, the patient runs on the spot for 1 minutes, sits up continuously, coughs forcefully 10 times, and bends over Take the action 5 times, and finally wash your hands with tap water for 1 minutes. After 1hours, the patient was instructed to take out the urine pad and weigh it, retain the urine and measure the urine volume. Urine leakage = 2g is positive; according to the amount of urine leakage, the degree of urinary incontinence can be divided: 2g=urine leakage <5g is mild, 5=urine leakage <10g is moderate, 10g=urine leakage <50g is severe, Urine leakage = 50g is considered extremely severe. Before treatment
Primary 1 hours urine pad test the patient empties the bladder before the test, and the urine pad is weighed and placed in the perineum. 0-15minutes, the patient drinks the mineral water prepared in advance; 16-45minutes, the patient walks as usual, going up and down the stairs; 46-60minutes, the patient runs on the spot for 1 minutes, sits up continuously, coughs forcefully 10 times, and bends over Take the action 5 times, and finally wash your hands with tap water for 1 minutes. After 1hours, the patient was instructed to take out the urine pad and weigh it, retain the urine and measure the urine volume. Urine leakage = 2g is positive; according to the amount of urine leakage, the degree of urinary incontinence can be divided: 2g=urine leakage <5g is mild, 5=urine leakage <10g is moderate, 10g=urine leakage <50g is severe, Urine leakage = 50g is considered extremely severe. 4 weeks
Primary International Consultation on Incontinence Questionnaire short form The patients reviewed their situation in the last 4 weeks, and scored three questions: the frequency of urine leakage, the amount of urine leakage, and the degree of impact on daily life. The minimum and maximum values were 0 and 21 respectively. The higher the total score, the more severe the symptoms of urinary incontinence, worse outcome. The greater the impact on life. 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04829357 - Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT04512053 - A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence Phase 2
Active, not recruiting NCT06224335 - Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
Recruiting NCT05304312 - The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women N/A
Not yet recruiting NCT05527665 - Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
Not yet recruiting NCT04558762 - Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
Withdrawn NCT02524366 - A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement N/A
Completed NCT01924728 - Efficacy of Magnetic Stimulation for Stress Urinary Incontinence N/A
Completed NCT01676662 - Solace European Confirmatory Trial N/A
Unknown status NCT01455779 - Lyrette: Renewing Continence Objective and Subjective Efficacy Study N/A
Terminated NCT01029106 - Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI) N/A
Completed NCT01123096 - Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence? N/A
Completed NCT01770691 - Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence N/A
Withdrawn NCT00573703 - Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence Phase 4
Completed NCT00234754 - Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women N/A
Completed NCT00441454 - Retropubic vs. Transobturator Tension-free Vaginal Tape N/A
Completed NCT03985345 - Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence. N/A
Active, not recruiting NCT03671694 - Laser Vaginal Treatment for SUI N/A
Completed NCT04097288 - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Phase 1